Press Release

PhRMA Urges President Obama on Ambitious TPP Agreement

PhRMA May 8, 2012

Washington, D.C. (May 8, 2012) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John Castellani issued the following statement today:

“PhRMA joins with a large group of U.S trade associations urging President Obama to complete his vision for a strong, ambitious Trans-Pacific Partnership Agreement (TPP) which would further economic growth by strengthening American trade with the Asia-Pacific region.

“When negotiators meet in Dallas, TX this week, it is imperative that progress is made toward a far reaching agreement that includes strong intellectual protections for American innovators. This Administration has recognize the key role fulfilled by the innovative and creative industries such as America’s research-based biopharmaceutical companies in driving economic growth, jobs and competitiveness here at home and abroad.  Strong IP protections, which ensure our companies can continue to innovate in the future, are key to these outcomes.

“As set out in the letter to President Obama, ’the adoption of strong IP protections by all countries in the TPP more widely promotes strong benefits for all, whether or not the country has developed its own major IP-based industries. Developed and developing countries that have adopted stronger IP protections have proven better able to develop their own technological, science, creative and other innovative and IP-dependent industries, advancing their own economic growth, productivity, exports, innovation and the interests of their workers and consumers alike.’

“This is especially true for the innovative biopharmaceutical industry.  We strongly urge that the United States redouble its efforts to secure a commercially meaningful agreement that incorporates high standards for the protection and enforcement of IP rights. This is critical to the future prosperity of the United States and its eight TPP negotiating partners.”

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $49.5 billion in 2011 in discovering and developing new medicines.

Find PhRMA Online:

For information on how innovative medicines save lives, visit:

For information on the Partnership for Prescription Assistance, visit:

For information on ensuring the flow of medicines during public health emergencies, visit